Type 2 Diabetes Trial, Not Yet Recruiting NCT07595289 Sponsor: The Third Xiangya Hospital of Central South University Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Not Yet Recruiting

NCT07595289
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are willing to take part and sign a consent form agreeing to join the study.
  • People aged between 18 and 60 years (inclusive), of any gender.
  • People who have been diagnosed with type 2 diabetes within the last 5 years, have not taken any blood sugar-lowering medication in the past 3 months, and have an HbA1c (a measure of average blood sugar over time) between 7% and 9%.
  • People who are willing and able to keep their diet and exercise habits consistent throughout the study.
  • People who are able to learn to use a smartphone, a continuous glucose monitor (a small device that tracks blood sugar), a blood sugar testing device, a smart scale, and a smart wristband with training provided by the study team.
  • People who, during an initial monitoring period, have their continuous glucose monitor recording data for at least 70% of the time.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have been diagnosed with, or are suspected of having, type 1 diabetes, a rare inherited form of diabetes, or diabetes caused by another medical condition.
  • People who experienced a serious diabetes-related emergency (such as diabetic ketoacidosis, hyperosmolar hyperglycemic state, or lactic acidosis) in the 3 months before screening.
  • People with high blood pressure that is not well controlled (top number 160 or higher and/or bottom number 100 or higher).
  • People with severe heart failure (classified as NYHA class III or IV, meaning significant limitations on physical activity) (confirm with trial site).
  • People with serious liver or kidney problems (based on specific blood and kidney function test results).
  • People with a history of cancer, autoimmune disease, serious infections, delayed stomach emptying (gastroparesis), other serious digestive conditions, or blood disorders.
  • People with a history of repeated urinary or genital tract infections.
  • People with alcohol misuse or alcohol-related liver disease.
  • People with a known or suspected allergy to a class of diabetes medications called SGLT-2 inhibitors (such as dapagliflozin) or to medical adhesives.
  • People who have taken any blood sugar-lowering medication in the past 3 months.
  • People who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  • People who, in the study team's judgment, have any medical, psychological, social, or practical circumstances that could affect their safety or the reliability of the study results.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 15974193674

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
The Third Xiangya Hospital of Central South University
Registry
ClinicalTrials.gov
Start date
1 August 2026
Est. completion
31 December 2026

Primary endpoints

Proportion of Participants Completing All DCT Procedures from Remote Informed Consent to Last Visit; Reliability Evaluation; Clinical Study Evaluation Indicators

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov